STELLATE GANGLION BLOCKADE FOR CHRONIC REFRACTORY ANGINA PECTORIS

Author(s):  
Sinem Sari
2021 ◽  
Vol 5 (8) ◽  
Author(s):  
Miroslav Hudec ◽  
Otakar Jiravsky ◽  
Radim Spacek ◽  
Radek Neuwirth ◽  
Lukas Knybel ◽  
...  

Abstract Background Refractory angina pectoris (AP) significantly impairs quality of life in patients with chronic coronary syndrome. Several minimally invasive methods (coronary sinus reducer, cell therapy, laser or shockwave revascularization, and spinal cord stimulation) or non-invasive methods (external counterpulzation) have been studied. However, their routine clinical use has not been widely implemented. Surgical or endoscopic sympathectomy is feasible for permanently relieving angina, but is often contraindicated due to the extent of complications associated with it. Neuromodulation by anaesthetic blockade of the left-sided stellate ganglion (SG) has been shown to relieve angina for days or weeks. To provide a long-term anti-anginal effect, novel pharmacological (phenol-based) or radiofrequency ablation techniques have been individually used to permanently destroy sympathetic pathways. Case summary We describe a first-in-man use of stereotactic radiosurgical SG ablation using a linear accelerator (CyberKnife) in a heart failure patient after myocardial infarction with chronic refractory AP. Repeated anaesthetic SG blockade in this patient resulted in a significant, but only short-term, clinical improvement. The left, and subsequently the right, SG was ablated by targeted irradiation. During the 1-year follow-up, the patient remained without angina. We did not observe any clinically relevant early or late complications. Atrial fibrillation that developed 2 months after the second procedure was deemed to be associated with a natural progression of co-existing heart failure. Discussion We conclude that stereotactic radiosurgical SG ablation has the potential to become a minimally invasive and low-risk procedure to treat refractory angina patients. However, this procedure needs to be evaluated in larger patient populations.


Author(s):  
Giulio Pompilio ◽  
Marco Gennari ◽  
Elisa Gambini ◽  
Beatrice Bassetti ◽  
Maurizio C.

2017 ◽  
Vol 02 (04) ◽  
pp. 094-098
Author(s):  
Meenakshi Kadiyala ◽  
Rameshwar Roopchandar ◽  
Chandrshekaran Krishnaswamy

AbstractBecause of improvement in survival from coronary artery disease and increasing life expectancy of the population, chronicity and resistance to therapy have become growing problems confronting the cardiologist. Refractory angina pectoris is an entity based on clinical diagnosis, and it refers to recurrent and sustained chest pain more than 3 months duration caused by coronary insufficiency that is unamenable to conventional modalities of treatment, including drugs, percutaneous coronary interventions, or coronary bypass grafting. Individuals with this entity may have an impaired quality of life, with recurrent angina, poor general health and psychological distress impairing functional and productive sustenance. A multitude of therapeutic options exists for patients with refractory angina pectoris, and randomized trials have shown them to be reasonably effective in reducing symptoms, though further research is warranted.


Sign in / Sign up

Export Citation Format

Share Document